Farm-originated Antimicrobial Resistance Modeling: Exploring Humans-to-Animal Dissemination (FARMHAND)

November 3, 2026 updated by: Centre Hospitalier de Saint-Brieuc

Farm-originated Antimicrobial Resistance Modeling: Exploring Humans-to-Animal Dissemination - FARMHAND

Antimicrobial resistance is a major public health issue. Methicillin resistance in Staphylococcus aureus (MRSA) is one of the indicators that is monitored particularly closely. In animals, pig farms, among others, have been identified as reservoirs of MRSA, with a risk of transmission to humans, particularly to individuals in direct contact with livestock. In France, the prevalence of MRSA in pig farms has increased markedly in recent years.

While cross-species transmission between pigs and humans in professional settings is well-documented, the temporal dynamics, the actual incidence of acquisition, and the associated determinants remain insufficiently characterized in France.

Adopting a "One Health" approach, this project aims to gain a better understanding of the mechanisms by which MRSA spreads between animal and human subpopulations and to incorporate these insights into a mathematical modeling framework.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The participants in this project will be farmers representing 20 different pig farms, the majority of which will be located in Brittany-a region recognized as the leading pork-producing area in France.

Participants will be asked to provide two types of samples, only one of which will contain personally identifiable data.

  • Nasal swabs: Participants in the study will be asked to perform a self-administered nasal swab once a month, at approximately the same time each month. This method was selected because it has demonstrated an acceptable level of participant compliance, as well as satisfactory validity for detecting S. aureus carriage in humans.
  • Dust samples: Participants will be asked to collect dust samples from the production floor-specifically in the room within the finishing facility that houses the oldest animals-by wiping surfaces with a small cloth. This method was chosen because dust in livestock-rearing environments has been identified as a reliable indicator of MRSA carriage status in pigs.

These successive samplings will be carried out over time in order to analyze carriage dynamics and estimate epidemiological parameters of interest. A modeling component will be incorporated to make use of the data collected.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
20

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • France
      • Ploufragan, France, 22440
        • Anses Ploufragan - Plouzané - Niort, site de Ploufragan
        • Contact:
          • Claire CHAUVIN, Dr
      • Saint-Brieuc, France, 22000
        • Centre Hospitalier de Saint-Brieuc - Paimpol - Tréguier, site de Saint-Brieuc
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 18 years of age or older,
  • Work full-time as a pig farmer on the participating farm,
  • Have regular contact with the animals, defined as at least 4 days per week,
  • Be willing to participate in the study and sign an informed consent form,
  • Agree to perform monthly self-administered nasal swab sampling and to provide data via a questionnaire.

Exclusion Criteria:

  • Refusal to participate or inability to provide informed consent,
  • Inability to perform monthly self-administered nasal swabs in accordance with the protocol,
  • Employment on a part-time basis, or status as an intern or apprentice within the operation,
  • No inclusion of persons targeted by Articles L. 1121-5 to L. 1121-8 and L. 1122-1-2 of the Public Health Code (e.g., minors, legally protected adults, etc.)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Farmers representing 20 different pig farms
Other: Sample collection

Participants will be asked to provide two types of samples, only one of which will contain personally identifiable information.

  • Nasal samples: a monthly self-collected nasal swab, performed at approximately the same time each month.
  • Dust samples: following the collection and storage of the nasal swab, participants will be asked to collect dust samples from the production area-specifically, from the room within the fattening facility that houses the oldest animals-by wiping surfaces using a small cloth.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
To estimate the prevalence of nasal carriage of MRSA among pig farmers during the study period.
Time Frame: From enrollment to the end of the study : 24 months

The primary outcome measure is the prevalence of nasal carriage of MRSA among pig farmers during the study period, as determined by microbiological detection from self-collected nasal swabs.
From enrollment to the end of the study : 24 months

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Describe the temporal dynamics of nasal carriage of Staphylococcus aureus among pig farmers and within farms.
Time Frame: From enrollment to the end of the study : 24 months

The prevalence of nasal carriage of MSSA among pig farmers.
From enrollment to the end of the study : 24 months
Estimate the incidence of acquisition and clearance of MRSA and MSSA among pig farmers and within farms, based on repeated longitudinal measurements.
Time Frame: From enrollment to the end of the study : 24 months

The incidence of acquisition and clearance of MRSA and MSSA among pig farmers, estimated from repeated longitudinal measurements of nasal carriage.
From enrollment to the end of the study : 24 months
Identify factors associated with the carriage and acquisition of MRSA among pig farmers.
Time Frame: From enrollment to the end of the study : 24 months

The prevalence and incidence of MSSA and MRSA within the pig farm environment.
From enrollment to the end of the study : 24 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Centre Hospitalier de Saint-Brieuc

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Institut Pasteur
National conservatory of arts and crafts (CNAM)
ANSES (Agence Nationale de Sécurité Sanitaire de l'alimentation, de l'environnement et du travail)

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 1, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
November 1, 2028

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
November 1, 2028

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
October 21, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 21, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
October 27, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 6, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 3, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
November 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2026_CHSB_FARMHAND
  • 2026-A01235-46 (Other Identifier: ID RCB)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings